The Real Price of UnitedHealth Stock Is Two Years Away

The healthcare giant looks expensive on today’s numbers, but a patient investor is effectively buying it at a significant discount to that price.

At a glance, UnitedHealth (UNH) stock looks pricey. Trading at about 31.9 times its last twelve months of reported earnings, it carries the kind of premium that makes many investors stop looking. But that headline number is a rearview mirror. The more telling price tag is the one you pay for the earnings analysts expect down the road.

The Discount Patience Buys You

On the earnings Wall Street expects by 2027, today’s price of $423.56 is no longer 31.9 times earnings, but about 19.0 times. That’s a 40% lower multiple. This is the forward valuation discount: as earnings grow into the price, the multiple you are effectively paying falls on its own. A patient holder isn’t buying the stock at today’s multiple; they are buying the 2027 earnings stream at that much lower 19.0 times multiple. A quick caveat: the trailing multiple is based on reported GAAP earnings, while forward estimates typically use a non-GAAP basis, so part of that drop reflects a difference in accounting, not just pure growth.

And UnitedHealth is far from alone: which 10 S&P 500 stocks carry the biggest hidden forward discount? Our rankings sort the entire index by how little you are really paying for each name’s growth once the out-year earnings land.

Is the Growth That Creates the Discount Believable?

A discount is only as good as the growth that creates it. Here, the analyst consensus seems grounded. For one, the 19 analysts covering the company are in a tight cluster on that 2027 earnings number. More importantly, management’s own guidance for 2026 adjusted earnings is a range of 19.50 to 20.00 per share, which neatly brackets the 2026 analyst consensus of $19.72. When management and analysts are aligned, the forecast carries more weight.

The growth itself appears conservative. Analysts expect revenue to grow just 1.1% a year through 2027. That’s well below the 9.7% revenue growth the company actually delivered over the last twelve months. On its latest call, management pointed to “operational improvement underway across the enterprise,” particularly in its Medicare business and the Optum Health segment. The key debate among analysts, which you can read more about, centers on whether these strengths can offset other pressures. The main challenge is in the commercial insurance business, where management noted that “medical cost trends” are delaying a full margin recovery “past 2027.”

The Payoff Is Not the Discount Itself

It’s crucial to understand how this pays off. If the stock price never moves, by 2027 you’d simply own a company trading at 19.0 times earnings. The discount just proves you didn’t overpay; it’s your margin of safety. The actual reward only comes if the market continues to award the stock a higher multiple as those earnings arrive.

For perspective, if the multiple settles at 25.5 times, roughly halfway between today’s premium and that 19.0 times floor, the stock would be about 34% higher. Of course, a stock priced for growth can be volatile. In past market shocks, UNH has fallen as much as 72%, a reminder that patience is required.

The Price You’re Really Paying

The premium you see on UnitedHealth today is not the full story. On 2027 earnings, you are paying a far more ordinary multiple. This suggests that even if the stock goes nowhere, a holder has not necessarily overpaid for the underlying business growth. The upside is conditional: if the market keeps valuing these shares at anything near today’s multiple as the new earnings baseline is established, the price should compound with them. The one metric to watch is the commercial medical cost trend; if the company can get that under control, the path for earnings growth becomes much clearer.

Own The Growth Without Overpaying

Whether you already hold UnitedHealth or you are weighing it now, the appeal is not that the stock is secretly cheap today. It is that you are not overpaying for the growth: on the earnings analysts expect two years out, you are paying an ordinary multiple, even if the price never moves.

The upside sits on top of that. If the market keeps paying anything close to today’s multiple as those earnings actually arrive, the price compounds with them. The one catch is that it all rides on a single company’s numbers coming through. And if it is exposure to healthcare as a whole you want rather than this one name, a healthcare ETF like XLV covers that sector, though that still leaves you riding a single slice of the market. That is why the Trefis High Quality (HQ) Portfolio does not lean on any single name: it uses this same valuation-discount discipline to size a measured allocation to strong growth like this, inside a diversified set of 30 high-conviction stocks, re-balanced as the estimates change and with a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000.